European Journal of Cardiovascular Medicine

Introduction: Vitiligo is an acquired pigmentary anomaly of the skin. It is manifested via de-pigmentary white patches on the skin with normal border or surrounding hyperpigmentation. Over the recent years, vitD (vitamin D) is implicated in a wide variety of medical conditions. It functions like a hormone and is produced in the skin where it plays an important role in skin pigmentation, increase enzyme action of tyrosinase and thus also affects melanin production. It also displays various immunoregulatory functions. VitD is found to be reduced in autoimmune diseases, like SLE, DM, alopecia areata, RA and multiple sclerosis.  Materials and methods: This is a prospective and case-control study was conducted. 120 vitiligo patients attending Department of Dermatology at R V M. Medical College, were included over a period of 6 months. Full history and examination were done, and the diagnosis was confirmed clinically and by using Wood’s light examination. In addition, 100 controls, age and sex matched, were included for comparison. Patients with vitiligo (generalized, focal, or segmental), normal thyroid function tests, and serum vitamin B12 were included in the study. In addition, clinical details of vitiligo were obtained including patient demographics, duration of vitiligo, and current and previous treatment.  Results: The demographic data of the 60 patients with vitiligo participating in this study. Comparison of mean VASI score calculated before and after treatment shows that the overall VASI score was significantly decreased relative to baseline (P<0.001).  Conclusion: Further studies are required to establish a causal relationship between vitiligo and vitD and likewise exploring the possibilities of use of vitD in treating vitiligo either alone or in combination with other therapies. The findings suggested there is no convincing evidence that vitamin D may help to prevent vitiligo.